The Journal of Immunology, Vol 144, Issue 5 1711-1720, Copyright © 1990 by American Association of Immunologists

ARTICLES

Use of synthetic peptides to establish anti-human acetylcholine receptor CD4+ cell lines from myasthenia gravis patients

MP Protti, AA Manfredi, C Straub, XD Wu, JF Howard Jr and BM Conti-Tronconi
Department of Biochemistry, University of Minnesota, St. Paul 55108.

Acetylcholine receptor-(AcChR) specific T cell lines were propagated from the PBL of six myasthenia gravis (MG) patients by the use of a pool of synthetic peptides (alpha-pool) corresponding to the complete sequence of the alpha-subunit of the human AcChR. All the lines had CD4+ phenotype and strongly recognized the alpha-pool. Four lines cross- reacted with native Torpedo AcChR. Five lines showed, at certain stages of their propagation, some degree of reactivity to autologous or DR- matched APC. One of the CD4+ T lines was challenged with each one of the peptides present in the alpha-pool. Several peptides, corresponding to the sequence segments 48-67, 101-120, 304-322, 320-337, and 419-437 of the human alpha-subunit were recognized, indicating that different epitopes and multiple T cell clones are involved in the recognition of the autoantigen in MG. Human AcChR-specific CD4+ T cell lines will be useful to identify the repertoire of epitopes recognized by the autoreactive Th cells in MG, to investigate the TCR genes utilized by autoreactive Th cells and to develop specific immunosuppressive treatments using anti-T cell vaccination.

This article has been cited by other articles:

				E. Tassi, V. Facchinetti, S. Seresini, A. Borri, G. Dell'Antonio, C. Garavaglia, G. Casorati, and M. P. Protti Peptidome from Renal Cell Carcinoma Contains Antigens Recognized by CD4+ T Cells and Shared among Tumors of Different Histology. Clin. Cancer Res., August 15, 2006; 12(16): 4949 - 4957. [Abstract] [Full Text] [PDF]

				M. Crosti, R. Longhi, G. Consogno, G. Melloni, P. Zannini, and M. P. Protti Identification of Novel Subdominant Epitopes on the Carcinoembryonic Antigen Recognized by CD4+ T Cells of Lung Cancer Patients. J. Immunol., April 15, 2006; 176(8): 5093 - 5099. [Abstract] [Full Text] [PDF]

				G. Campi, M. Crosti, G. Consogno, V. Facchinetti, B. M. Conti-Fine, R. Longhi, G. Casorati, P. Dellabona, and M. P. Protti CD4+ T Cells from Healthy Subjects and Colon Cancer Patients Recognize a Carcinoembryonic Antigen-specific Immunodominant Epitope Cancer Res., December 1, 2003; 63(23): 8481 - 8486. [Abstract] [Full Text] [PDF]

				G. Consogno, S. Manici, V. Facchinetti, A. Bachi, J. Hammer, B. M. Conti-Fine, C. Rugarli, C. Traversari, and M. P. Protti Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3 Blood, February 1, 2003; 101(3): 1038 - 1044. [Abstract] [Full Text] [PDF]

				M. A. Imro, S. Manici, V. Russo, G. Consogno, M. Bellone, C. Rugarli, C. Traversari, and M. P. Protti Major Histocompatibility Complex Class I Restricted Cytotoxic T Cells Specific for Natural Melanoma Peptides Recognize Unidentified Shared Melanoma Antigen(s) Cancer Res., May 1, 1999; 59(10): 2287 - 2291. [Abstract] [Full Text] [PDF]

				S. Manici, T. Sturniolo, M. A. Imro, J. Hammer, F. Sinigaglia, C. Noppen, G. Spagnoli, B. Mazzi, M. Bellone, P. Dellabona, et al. Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 J. Exp. Med., March 1, 1999; 189(5): 871 - 876. [Abstract] [Full Text] [PDF]

				D. B. Drachman Myasthenia Gravis N. Engl. J. Med., June 23, 1994; 330(25): 1797 - 1810. [Full Text]